Journal of the Korean Society of Radiology (대한영상의학회지)

The Korean Society of Radiology (대한영상의학회)
권호 표지

Factors Affecting $^{18}F$-Fluorodeoxyglucose (FDG) Uptake in Breast Cancer

유방암에서 $^{18}F$-Fluorodeoxyglucose (FDG) 섭취도에 영향을 미치는 요인들

  • Jeong, Sun-Hye (Department of Radiology, Soonchunhyang University Bucheon Hospital) ;
  • Lee, Eun-Hye (Department of Radiology, Soonchunhyang University Bucheon Hospital) ;
  • Park, Jung-Mi (Department of Nuclear Medicine, Soonchunhyang University Bucheon Hospital) ;
  • Lee, Hae-Kyung (Department of Radiology, Soonchunhyang University Bucheon Hospital) ;
  • Yi, Boem-Ha (Department of Radiology, Soonchunhyang University Bucheon Hospital) ;
  • Choi, Na-Mi (Department of Radiology, Konkuk University Hospital)
  • 정선혜 (순천향대학교 부천병원 영상의학과) ;
  • 이은혜 (순천향대학교 부천병원 영상의학과) ;
  • 박정미 (순천향대학교 부천병원 핵의학과) ;
  • 이혜경 (순천향대학교 부천병원 영상의학과) ;
  • 이범하 (순천향대학교 부천병원 영상의학과) ;
  • 최나미 (건국대학교병원 영상의학과)
  • Received : 2009.09.08
  • Accepted : 2010.06.20
  • Published : 2010.09.01
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate factors affecting $^{18}F$-Fluorodeoxyglucose (FDG) uptake in breast cancer. Materials and Methods: For 3 years from 2006, 180 patients (mean age 48-years-old) with 187 breast cancers underwent positron emission tomography-computed tomography (PET/CT; biograph2, Siemens) at our institute and were enrolled in this study. We evaluated whether there was a correlation between the peak standardized uptake value (pSUV) of PET/CT and the histologic type of the breast cancers (n=187), grade of the invasive ductal cancers (n=142), and tumor size (n=153). Results: The different histologic types of breast cancers include IDCs (n=156), in situ ductal carcinoma (n=10), papillary cancer (n=6), mucinous cancer (n=6), invasive lobular cancer (n=4), medullary cancer (n=3), metaplastic cancer (n=1), and neuroendocrine cancer (n=1). pSUV showed significant differences according to histologic type (p<0.005). For the available cases (n=142), IDCs were classified as grade 1 (n=25), grade 2 (n=66), and grade 3 (n=51) and correlated with the histologic grade of IDCs (rho=0.41, p<0.001). pSUV was correlated with tumor size regardless of histologic type (rho=0.525, p<0.001). In low grade IDCs, pSUV was correlated with tumor size (rho=0.48-0.86, p<0.001), but not in high grade IDCs (p>0.001). Conclusion: Regardless of histologic type, the larger the breast cancer, the higher the pSUV; in addition, the higher the grade of IDCs, the higher the pSUV. For the low grade IDCs, pSUV is correlated with tumor size; however, this is not the case in high grade IDCs.

목적: 유방암의 $^{18}F$-Fluorodeoxyglucose (FDG) 섭취도에 영향을 미치는 요인들을 알아보고자 하였다. 대상과 방법: 2006년 4월부터 3년간 본원에서 positron emission tomography/computed tomography (PET/CT)를 시행한 유방암환자 180명(평균나이, 48세)의 187개 병변을 대상으로 하였다. PET/CT는 이중 검출기가 장착된 장비(Biograph2, Siemens)를 이용하였다. 최대 표준섭취계수(peak standardized uptake value, 이하 pSUV)와 조직학적 유형(n=187), 등급(n=142), 병변의 크기(n=153)간의 관계를 분석하였다. 결과: 조직학적 유형은 침습관상피암 156개, 관상피내암 10개, 유두암과 점액암 각각 6개, 침습소엽암 4개, 수질암 3개였으며, 그밖에 화생성암, 신경내분비암이 각각 1개였다. 조직학적 유형에 따라 pSUV에 차이가 있었다(p < 0.005). 등급을 알 수 있었던 침습관상피암 142개는 1등급 25개, 2등급 66개, 3등급 51개였으며 침습관상피암의 등급이 높을수록 pSUV가 높았다(rho=0.41, p < 0.001). 전반적으로 유방암의 조직학적 유형에 관계없이 병변이 클수록 pSUV가 높았다(rho=0.525, p < 0.001). 침습관상피암은 저등급에서는 크기가 클수록 pSUV가 높았지만(rho=0.48-0.86, p < 0.001) 고등급에서는 크기와 pSUV 사이에 상관관계를 보이지 않았다(p > 0.001). 결론: 유방암의 조직학적 유형에 상관없이 병변이 클수록 pSUV가 높았다. 침습관상피암은 등급이 높을수록 pSUV가 높았다. 저등급 침습관상피암에서는 병변이 클수록 pSUV가 높았으나 고등급은 크기와 pSUV간에 상관관계가 없었다.

Keywords

References

  1. 오기근, 문우경, 손은주, 김미혜, 정수영, 고경란 등. 유방질환의 영상검사. In 정수영, 한부경, 대한유방영상의학회. 유방영상진단학. 일조각. 2008:121
  2. Rosen EL, Eubank WB, Mankoff DA, FDG PET, PET/CT, and breast cancer imaging. Radiographics 2007;27:S215-S229 https://doi.org/10.1148/rg.27si075517
  3. Lim HS, Yoon W, Chung TW, Kim JK, Park JG, Kang HK, et al. FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations. Radiographics 2007;27:S197-S213 https://doi.org/10.1148/rg.27si075507
  4. Noh DY, Yun IJ, Kim JS, Kang HS, Lee DS, Chung JK, et al. Diagnostic value of positron emission tomography for detecting breast cancer. World J Surg 1998;22:223-228 https://doi.org/10.1007/s002689900374
  5. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991;179:765-770 https://doi.org/10.1148/radiology.179.3.2027989
  6. Crowe JP, Adler LP, Shenk RR, Sunshine J. Positron emission tomography and breast masses comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1994;1:132-140 https://doi.org/10.1007/BF02303557
  7. Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998; 39:431-435
  8. Palmedo H, Bender H, Grunwald F, Mallmann P, Zamora P, Krebs D, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99 m methoxyisobuty lisonitrile scintimammography in the detection of breast tumours. Eur J Nucl Med 1997;24:1138-1145
  9. Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 2006;98:267-274 https://doi.org/10.1007/s10549-006-9159-2
  10. Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000;18: 3495-3502
  11. Samson DJ, Flamm CR, Pisano ED, Aronson N. Should FDG PET be used to decide whether a patient with an abnormal mammogram or breast finding at physical examination should undergo biopsy? Acad Radiol 2002;9:773-783 https://doi.org/10.1016/S1076-6332(03)80347-1
  12. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2- fluoro-D-glucose PET. Radiology 1993;187:743-750
  13. Schirrmeister H, Kuhn T, Guhlmann A, Santjohanser C, Horster T, Nussel K, et al. Fluorine-182-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001;28:351-358 https://doi.org/10.1007/s002590000448
  14. Kumar R, Alavi A. Fluorodeoxyglucose-PET in the management of breast cancer. Radiol Clin North Am 2004;42:1113-1122 https://doi.org/10.1016/j.rcl.2004.08.005
  15. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005;35:84-99 https://doi.org/10.1053/j.semnuclmed.2004.11.001
  16. Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A, et al. Association between [$^{18}F$]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 1998;25:1429-1434 https://doi.org/10.1007/s002590050319
  17. Avril N, Menzel M, Dose J, Schelling M, Weber W, Janicke F, et al. Glucose metabolism of breast cancer assessed by $^{18}F$-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001;42:9-16
  18. Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002; 29:1317-1323 https://doi.org/10.1007/s00259-002-0880-8
  19. Buck A, Schirrmeister H, Mattfeldt T, Reske SN. Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging 2004;31 Suppl 1:S80-S87 https://doi.org/10.1007/s00259-004-1529-6
  20. 유정현, 최혜영, 안세현. 유방X-선 촬영술에서 오진한 유방암의 후향적 연구. 대한방사선의학회지 1995;32:501-506
  21. 박현주, 한 현, 임달모, 정효선, 김지은, 김영채. 유방암의 X-선유방 촬영술 소견의 분석. 대한방사선의학회지 1995;32:337-342